Ignite Creation Date:
2024-05-06 @ 10:08 AM
Last Modification Date:
2024-10-26 @ 12:25 PM
Study NCT ID:
NCT03178071
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2019-11-04
First Post:
2017-06-02
Brief Title:
Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Sponsor:
Organization:
Pfizer